vs
Side-by-side financial comparison of ACNB CORP (ACNB) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $47.2M, roughly 1.8× ACNB CORP). On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 17.7%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 22.1%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ACNB vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $86.8M |
| Net Profit | $10.8M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 27.9% | -84.7% |
| Net Margin | 22.9% | — |
| Revenue YoY | 42.2% | 17.7% |
| Net Profit YoY | 63.8% | — |
| EPS (diluted) | $1.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $86.8M | ||
| Q3 25 | $50.9M | $67.5M | ||
| Q2 25 | $50.3M | $60.0M | ||
| Q1 25 | $43.5M | $49.3M | ||
| Q4 24 | $33.2M | $73.7M | ||
| Q3 24 | $34.1M | $58.6M | ||
| Q2 24 | $33.3M | $31.1M | ||
| Q1 24 | $31.6M | $715.0K |
| Q4 25 | $10.8M | — | ||
| Q3 25 | $14.9M | $-91.3M | ||
| Q2 25 | $11.6M | $-111.7M | ||
| Q1 25 | $-272.0K | $-116.2M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $7.2M | $-83.5M | ||
| Q2 24 | $11.3M | $-97.1M | ||
| Q1 24 | $6.8M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 27.9% | -84.7% | ||
| Q3 25 | 37.2% | -140.7% | ||
| Q2 25 | 29.7% | -189.8% | ||
| Q1 25 | -1.3% | -245.8% | ||
| Q4 24 | 24.8% | -117.5% | ||
| Q3 24 | 27.6% | -152.1% | ||
| Q2 24 | 42.8% | -327.6% | ||
| Q1 24 | 26.9% | -16464.6% |
| Q4 25 | 22.9% | — | ||
| Q3 25 | 29.2% | -135.3% | ||
| Q2 25 | 23.2% | -186.2% | ||
| Q1 25 | -0.6% | -235.5% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 21.1% | -142.7% | ||
| Q2 24 | 33.9% | -312.2% | ||
| Q1 24 | 21.4% | -15800.8% |
| Q4 25 | $1.10 | — | ||
| Q3 25 | $1.42 | — | ||
| Q2 25 | $1.11 | $-0.33 | ||
| Q1 25 | $-0.03 | $-0.36 | ||
| Q4 24 | $0.77 | $-0.24 | ||
| Q3 24 | $0.84 | $-0.28 | ||
| Q2 24 | $1.32 | $-0.34 | ||
| Q1 24 | $0.80 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $297.0M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $698.6M |
| Total Assets | $3.2B | $913.2M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $297.0M | ||
| Q3 25 | $102.1M | $300.8M | ||
| Q2 25 | $103.1M | $301.2M | ||
| Q1 25 | $123.6M | $359.7M | ||
| Q4 24 | $47.3M | $323.8M | ||
| Q3 24 | $58.1M | $397.5M | ||
| Q2 24 | $86.3M | $412.5M | ||
| Q1 24 | $53.1M | $356.2M |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $698.6M | ||
| Q3 25 | $408.6M | $702.3M | ||
| Q2 25 | $395.2M | $698.5M | ||
| Q1 25 | $386.9M | $767.9M | ||
| Q4 24 | $303.3M | $710.4M | ||
| Q3 24 | $306.8M | $773.5M | ||
| Q2 24 | $289.3M | $768.5M | ||
| Q1 24 | $279.9M | $680.0M |
| Q4 25 | $3.2B | $913.2M | ||
| Q3 25 | $3.3B | $904.9M | ||
| Q2 25 | $3.3B | $907.4M | ||
| Q1 25 | $3.3B | $966.7M | ||
| Q4 24 | $2.4B | $910.4M | ||
| Q3 24 | $2.4B | $991.1M | ||
| Q2 24 | $2.5B | $964.3M | ||
| Q1 24 | $2.4B | $869.8M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $-52.6M |
| Free Cash FlowOCF − Capex | $52.6M | $-61.9M |
| FCF MarginFCF / Revenue | 111.4% | -71.3% |
| Capex IntensityCapex / Revenue | 2.3% | 10.7% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $-52.6M | ||
| Q3 25 | $23.2M | $-78.7M | ||
| Q2 25 | $17.8M | $-67.4M | ||
| Q1 25 | $-71.0K | $-103.7M | ||
| Q4 24 | $39.8M | $-73.3M | ||
| Q3 24 | $13.6M | $-59.0M | ||
| Q2 24 | $9.7M | $-98.4M | ||
| Q1 24 | $10.8M | $-122.3M |
| Q4 25 | $52.6M | $-61.9M | ||
| Q3 25 | $22.8M | $-89.5M | ||
| Q2 25 | $17.6M | $-74.9M | ||
| Q1 25 | $-730.0K | $-109.9M | ||
| Q4 24 | $38.8M | $-77.5M | ||
| Q3 24 | $13.3M | $-61.3M | ||
| Q2 24 | $9.4M | $-98.9M | ||
| Q1 24 | $10.7M | $-126.5M |
| Q4 25 | 111.4% | -71.3% | ||
| Q3 25 | 44.7% | -132.7% | ||
| Q2 25 | 35.0% | -124.9% | ||
| Q1 25 | -1.7% | -222.8% | ||
| Q4 24 | 117.0% | -105.1% | ||
| Q3 24 | 39.1% | -104.6% | ||
| Q2 24 | 28.3% | -317.9% | ||
| Q1 24 | 33.9% | -17685.3% |
| Q4 25 | 2.3% | 10.7% | ||
| Q3 25 | 0.8% | 16.1% | ||
| Q2 25 | 0.4% | 12.4% | ||
| Q1 25 | 1.5% | 12.6% | ||
| Q4 24 | 2.9% | 5.7% | ||
| Q3 24 | 0.7% | 3.9% | ||
| Q2 24 | 0.9% | 1.4% | ||
| Q1 24 | 0.2% | 583.4% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
